ArticleVaccine2018
The future control of rotavirus disease: Can live oral vaccines alone solve the rotavirus problem?
Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Associations Between Histo-blood Group Antigen Status in Mother-Infant Dyads and Infant Oral Rotavirus Vaccine Immunogenicity in Rural Zimbabwe.The Journal of infectious diseases · 2025Trial
- Head-to-head comparison of the immunogenicity of RotaTeq and Rotarix rotavirus vaccines and factors associated with seroresponse in infants in Bangladesh: a randomised, controlled, open-label, parallel, phase 4 trial.The Lancet. Infectious diseases · 2022Trial
- Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.The Lancet. Infectious diseases · 2020Trial
- Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.The Lancet. Infectious diseases · 2020Trial
- Rapid development of a robust cultivation process for subunit rotavirus vaccine antigen expression in Escherichia coli with the quality by design approach.Bioprocess and biosystems engineering · 2026Article
- Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990-2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2025Article
- Genetic characterization of two G8P[8] rotavirus strains isolated in Guangzhou, China, in 2020/21: evidence of genome reassortment.BMC infectious diseases · 2022Article
- Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine.NPJ vaccines · 2022Article
- National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study.Vaccine · 2022Article
- The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease.The Journal of infectious diseases · 2021Article
- The Rotavirus Vaccine Landscape, an Update.Pathogens (Basel, Switzerland) · 2021Review
- Winning the Battle Against Rotavirus Diarrhea…One Step at a Time.The Journal of infectious diseases · 2020Article
- Rotavirus symptomatic infection among unvaccinated and vaccinated children in Valencia, Spain.BMC infectious diseases · 2019Article
- Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi.Science translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Live oral rotavirus (RV) vaccines used worldwide are most effective in reducing diarrheal hospitalizations from RV in high income countries and least effective in low income countries where RV remains a prime cause of death in children. Research has failed to fully explain the reason for this difference of efficacy for RV vaccines, an observation made with other live oral vaccines for polio, cholera and typhoid fever. Use of parenteral vaccines have been successful in overcoming this problem for both polio and typhoid and parenteral RV vaccines are now in development. This approach should be pursued for rotavirus vaccine as well because in low income countries where oral RV vaccines have been introduced and are only partially effective, RV remains the most common cause of diarrhea in children under 5 years. The ultimate control of RV diarrheal will likely require both oral and parenteral vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.